Bayer CropScience Limited
Bayer CropScience Limited Fundamental Analysis
Bayer CropScience Limited (BAYERCROP.NS) shows moderate financial fundamentals with a PE ratio of 31.70, profit margin of 11.92%, and ROE of 22.52%. The company generates $56.2B in annual revenue with moderate year-over-year growth of 7.19%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 65.8/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze BAYERCROP.NS's fundamental strength across five key dimensions:
Efficiency Score
ExcellentBAYERCROP.NS demonstrates superior asset utilization.
Valuation Score
WeakBAYERCROP.NS trades at a premium to fair value.
Growth Score
ModerateBAYERCROP.NS shows steady but slowing expansion.
Financial Health Score
ExcellentBAYERCROP.NS maintains a strong and stable balance sheet.
Profitability Score
WeakBAYERCROP.NS struggles to sustain strong margins.
Key Financial Metrics
Is BAYERCROP.NS Expensive or Cheap?
P/E Ratio
BAYERCROP.NS trades at 31.70 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, BAYERCROP.NS's PEG of 3.14 indicates potential overvaluation.
Price to Book
The market values Bayer CropScience Limited at 6.80 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 26.23 times EBITDA. This signals the market has high growth expectations.
How Well Does BAYERCROP.NS Make Money?
Net Profit Margin
For every $100 in sales, Bayer CropScience Limited keeps $11.92 as profit after all expenses.
Operating Margin
Core operations generate 16.27 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $22.52 in profit for every $100 of shareholder equity.
ROA
Bayer CropScience Limited generates $12.91 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Bayer CropScience Limited generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
Bayer CropScience Limited generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
BAYERCROP.NS converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
31.70
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
3.14
vs 25 benchmark
P/B Ratio
Price to book value ratio
6.80
vs 25 benchmark
P/S Ratio
Price to sales ratio
3.78
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.03
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.29
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.23
vs 25 benchmark
ROA
Return on assets percentage
0.13
vs 25 benchmark
ROCE
Return on capital employed
0.28
vs 25 benchmark
How BAYERCROP.NS Stacks Against Its Sector Peers
| Metric | BAYERCROP.NS Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 31.70 | 27.18 | Worse (Expensive) |
| ROE | 22.52% | 860.00% | Weak |
| Net Margin | 11.92% | -121084.00% (disorted) | Strong |
| Debt/Equity | 0.03 | 0.41 | Strong (Low Leverage) |
| Current Ratio | 2.29 | 4.81 | Strong Liquidity |
| ROA | 12.91% | -7173.00% (disorted) | Strong |
BAYERCROP.NS outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Bayer CropScience Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
51.64%
Industry Style: Cyclical, Commodity, Value
High GrowthEPS CAGR
19.70%
Industry Style: Cyclical, Commodity, Value
High GrowthFCF CAGR
-54.92%
Industry Style: Cyclical, Commodity, Value
Declining